Stada Arzneimi Stock Price, News & Analysis (OTCMKTS:STDAF)

$93.75 0.00 (0.00 %)
(As of 11/20/2017 04:00 PM ET)
Previous Close$93.75
Today's Range$93.75 - $93.75
52-Week Range$47.53 - $97.45
VolumeN/A
Average Volume14 shs
Market Capitalization$5.84 billion
P/E Ratio27.74
Dividend YieldN/A
Beta1.42

About Stada Arzneimi (OTCMKTS:STDAF)

Stada Arzneimi logo


Industry, Sector and Symbol:
  • Industry: N/A
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: OTCMKTS:STDAF
  • Previous Symbol: NASDAQ:STDAF
  • CUSIP: N/A
  • Web: www.stada.de
Price-To-Earnings:
  • Trailing P/E Ratio: 27.74
Sales & Book Value:
  • Annual Sales: $2.36796 billion
  • Price / Sales: 2.47
  • Book Value: N/A
  • Price / Book: N/A
Misc:
  • Outstanding Shares: 62,340,000
 

Frequently Asked Questions for Stada Arzneimi (OTCMKTS:STDAF)

What is Stada Arzneimi's stock symbol?

Stada Arzneimi trades on the OTCMKTS under the ticker symbol "STDAF."

When will Stada Arzneimi make its next earnings announcement?

Stada Arzneimi is scheduled to release their next quarterly earnings announcement on Thursday, November, 23rd 2017. View Earnings Estimates for Stada Arzneimi.

Who are some of Stada Arzneimi's key competitors?

How do I buy Stada Arzneimi stock?

Shares of Stada Arzneimi can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stada Arzneimi's stock price today?

One share of Stada Arzneimi stock can currently be purchased for approximately $93.75.

How big of a company is Stada Arzneimi?

Stada Arzneimi has a market capitalization of $5.84 billion and generates $2.36796 billion in revenue each year.

How can I contact Stada Arzneimi?

Stada Arzneimi's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at 49-6101-6030.


MarketBeat Community Rating for Stada Arzneimi (OTCMKTS STDAF)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Stada Arzneimi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Stada Arzneimi (OTCMKTS:STDAF)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Sell (Score: 1.00)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Stada Arzneimi (OTCMKTS:STDAF)

Price Target History for Stada Arzneimi (OTCMKTS:STDAF)

Analysts' Ratings History for Stada Arzneimi (OTCMKTS:STDAF)

Show:
DateFirmActionRatingPrice TargetDetails
11/9/2017DZ Bank AGReiterated RatingSellView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History for Stada Arzneimi (OTCMKTS:STDAF)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Stada Arzneimi (OTCMKTS:STDAF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Stada Arzneimi (OTCMKTS:STDAF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Stada Arzneimi (OTCMKTS STDAF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Stada Arzneimi (OTCMKTS STDAF)

Source:
No headlines for this company have been tracked by MarketBeat.com

Social Media

Financials

Financials are not available for this stock.

Chart

Stada Arzneimi (OTCMKTS STDAF) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.